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Abstract
• Estrogen receptor positive breast cancer is the most common type of breast 
cancer, comprising roughly 80% of all breast cancers (Du et al. 2012). 
• Many therapies aim at blocking these estrogen receptors and/or reducing the 
amount of circulating estrogen in the body that has the potential to bind.
• Some researchers have encouraged the intake of soy supplements as a form of 
breast cancer prevention.
• However, some researchers argue that soy products contain specific 
compounds, known as soy isoflavones, that have the ability to mimic estrogen, 
potentially reversing the anti-estrogenic effects of these therapies. 
• Is the consumption of soy proto-oncogenic in patients with estrogen receptor 
positive breast cancer compared to the same patients who do not ingest soy?
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Introduction
Methods
• Literature Search performed in November 2018:
• Google Scholar
• PubMed
• 12 articles selected, excluding meta-analyses and literature reviews, on the 
following basis:
• Year of publication (2008-2018)
• Number of referenced citations (100+)
• Unique clinical trial
• 6 articles were then intimately compared and analyzed based on study design 
and results
The 6 compared studies demonstrate adequate evidence to suggest a link exists between soy consumption 
and breast cancer cell growth. However, the studies present various sources of bias and inadequacy, 
including limited sample sizes and length of study, as well as variable sources of soy. More research is 
necessary to assess the magnitude of the impact that genistein, daidzein and other sources of soy have on 
the growth and recurrence of breast cancer cells in estrogen receptor positive breast cancer patients. 
Current and anticipated challenges of research:
• Sample size and length of study may be impacted by tumor burden (ethics) and/or loss 
of life of participants in animal and human studies 
• Animal vs. human studies may have varying results
• In vitro studies are unable to take into account variability in patient demographics or 
lifestyle that may also impact results
Discussion 
Table 1. Example Table  
Results 
Soy Ingestion in Patients with 
Estrogen Receptor Positive Breast Cancer
Soy ingestion has become a significant topic of debate in the breast cancer community, as it is recognized for 
both its potential benefits and detrimental impacts on estrogen receptor positive breast cancer cells. Of the 
six articles critically analyzed and compared in this PICO discussion, they all conclude with evidence that 
suggests that soy ingestion in patients with estrogen receptor positive breast cancer results in increased 
growth of breast cancer cells and/or increased expression of breast cancer-related genes. However, while 
the articles discuss the impacts of genistein, daidzein and other soy isoflavones, they fail to discuss the 
specific food items that patients may have ingested, specifically in the cohort studies, that led to increased 
breast cancer cell growth. The studies also present several limitations including length of study, sample size 
and moral dilemmas. It is therefore essential that more research strategies be carefully designed and carried 
out to better understand the evident link that exists between soy products and estrogen receptor positive 
breast cancer. 
The 6 articles analyzed concur that soy ingestion has an undoubtable impact on estrogen receptor 
positive breast cancer. We should still wonder, however: 
• What is the magnitude?
• How do these results specifically impact pre-, peri-, and post-menopausal women?
• Which specific foods are the soy-containing culprits of a “typical” diet?
• How can we design more in vivo studies without compromising human comfort, morals and outcomes?
Conclusion
Figure 1: Poschner et al. 2017
Du M, Yang X, Hartman JA, et al. Low-dose dietary genistein negates the therapeutic effect of tamoxifen in 
athymic nude mice. Carcinogenesis. 2012;33(4):895-901. doi: 10.1093/carcin/bgs017. 
-100 mice were injected with 10,000 MCF-7 breast cancer cells each, and additionally injected with either 
estrogen alone, estrogen + tamoxifen, estrogen + tamoxifen + soy isoflavone genistein, or no additional 
injections (representing estrogen receptor negative breast cancer). Tumor growth was then measured in each 
mouse for 35 weeks. 
-Tamoxifen quells estrogen receptor positive breast cancer cell growth
-Soy isoflavone genistein ingestion negates effects of Tamoxifen, augmenting tumor growth 
in these patients
Johnson KA, Vemuri S, Alsahafi S, Castillo R and Cheriyath V. Glycone-rich soy isoflavone extracts promote 
estrogen receptor positive breast cancer cell growth. Nutrition and Cancer. 2016;68(4):622-633. doi: 
10.1080/01635581.2016.1154578. 
-54 commercial soybean strains with varying soy isoflavone extracts were injected into 24 separate plates of 
MCF-7 breast cancer cells; incubated for 2 weeks; some plates treated with Tamoxifen
-the soy isoflavone daidzein resulted in greatest breast cancer cell growth
-all soy isoflavone extracts augmented tumor cell growth in all plates, including those 
treated with Tamoxifen 
Koo J, Cabarcas-Petroski S, Petrie JL, Diette N, White RJ, Schramm L. Induction of proto-oncogene BRF2 in 
breast cancer cells by the dietary soybean isoflavone daidzein. BMC Cancer. 2015;15(1):1-11. 
doi:10.1186/s12885-015-1914-5. 
-quantified BRF2 gene expression (in breast and lung cancer) at 24, 48 and 72 hours in plates of MCF-7 and MDA-
MB-231 breast cancer cells (both estrogen receptor positive and negative) incubated and treated with either 
daidzein or no treatment 
-daidzein treatment resulted in increased expression of BRF2 in all plates
-greater proto-oncogenic gene expression in plates of estrogen receptor positive breast 
cancer cells
Poschner S, Maier-Salamon A, Zehl M, et al. The Impacts of genistein and daidzein on estrogen conjugations in 
human breast cancer cells: A targeted metabolomics approach. Frontiers in Pharmacology. 2017;8(699). 
doi:10.3389/fphar.2017.00699. 
-target: identifying impacts of high supplementary doses of genistein and daidzein compared to levels found in a 
typical patient’s diet; performed through kinetic analysis of estrogen product formation (assessing rate of 
estrogen receptor positive breast cancer cell growth when exposed to soy isoflavones)
-dose-dependent proto-oncogenic effect of soy isoflavones up until 100nM --> no further 
increase in MCF-7 breast cancer cell growth (unknown quantity in “typical patient’s diet”)
-daidzein resulted in 54% increase in growth; genistein 42%
Setch ll KD, Brown NM, Zh o X, et al. Soy isoflavone phase II metabolism differs between rodents and 
humans: implications for the effect on breast cancer risk. The American Journal of Clinical Nutrition. 
2011;94(5):1284-1294. doi:10.3945/ajcn.111.019638. 
-rats vs. humans: fed soy-free vs. soy-containing diet for > 1 week with blood levels of soy isoflavones measured 
after 1 week
-levels among different rats varied
-levels varied in humans depending on type of soy ingested
-no data in rats or humans with breast cancer of any type
Shike M, Doane AS, Russo L, et al. The effects of soy supplementation on gene expression in breast cancer: A 
randomized placebo-controlled study. JNCI Journal of the National Cancer Institute. 2014;106(9):1-12. 
doi:10.1093/jnci/dju189. 
-randomized placebo-controlled study: 140 women split into 2 groups, receiving soy supplement vs. placebo x 30 
days; 202 breast cancer-related genes analyzed with regard to level of gene expression in plasma
-In soy supplement group: 14 breast cancer-related genes with significant changes in gene 
expression: 10 increased, 4 decreased expression 
-In placebo group: 10 breast cancer-related genes with significant changes in gene 
expression: 5 increased, 5 decreased expression
Soy is a compound that is often touted for its potential health benefits, including 
for its potential ability to prevent the development of breast cancer. However, 
many researchers and medical providers present evidence that reveals the 
harmful effects that soy may have on various types of breast cancer, namely 
estrogen receptor positive breast cancer. The latter group of researchers argue 
that soy chemically mimics estrogen and therefore has similar “feeding” effects 
on estrogen receptor positive breast cancer. As two very distinct groups of 
evidence exist regarding the potential benefits and harm of soy ingestion in 
patients with estrogen receptor positive breast cancer, this PICO evaluation will 
examine the problem at hand in an attempt to draw an educated and evidence-
based conclusion with regard to the effects of soy consumption in these 
patients. 
• Breast cancer may be estrogen receptor positive or estrogen receptor negative. If it is estrogen receptor 
positive, it is likely to receive signals from estrogen that would increase breast cancer cell growth by 
turning “on” these receptors. Many drugs used in the treatment of estrogen receptor positive breast 
cancer aim to diminish levels of estrogen in the body and/or turn “off” these receptors.
• MCF-7 breast cancer cells: often non-metastatic, early-stage estrogen receptor positive cells that 
respond to estrogen both in vitro and in vivo
• Tamoxifen: Selective estrogen receptor modulator (SERM), used in estrogen receptor positive breast 
cancer; binds to the estrogen receptors, preventing estrogen’s proto-oncogenic effect 
• Soy isoflavones: natural compounds found in soy products that are believed to be phytoestrogens, 
mimicking the effects of estrogen in the body; genistein and daidzein are most common
• Equol: a phytoestrogen metabolite of daidzein
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